Namely, this participant presented with an ER+/PR+/HER2+ BC (HER2E expression subtype), where it was noted that the clinical HER2 immunohistochemistry (IHC) result was 2+ and fluorescence in situ hybridization (FISH) inconclusive but was HERmark assay positive. This evidence concerns the gene ERBB2 and breast cancer.